UNSPSC 51142650: Orlistat

This classification denotes a gastrointestinal lipase inhibitor with the molecular formula C29H53NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 95M8R751W8, chemically known as n-formyl-l-leucine, ester with (3s,4s)-3-hexyl-4-((2s)-2-hydroxytridecyl)-2-oxetanone but generally known as orlistat, which bears US NIH Compound Identifier 3034010. European Medicines Agency schedules Orlistat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09460MIG.

UNSPSC 51142650 Orlistat is a Commodity code that nominally names a specific weight-loss pharmaceutical, but recent state and local solicitation activity under this code does not align with procurement of orlistat itself. Instead, issuing bodies are using this code to tag broader pharmaceutical and over-the-counter product procurement, including naloxone, generic multi-source drugs, and direct-to-manufacturer prescription programs. The work actually being bought reflects state health agencies, counties, and cooperative purchasing alliances sourcing pharmaceuticals, medical supplies, and drug-related systems to support community health, pharmacy benefit programs, and emergency response initiatives. Issuing bodies span county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and multistate cooperative purchasing organizations (Minnesota MMCAP).

Recent activity concentrates in Florida, Texas, and Minnesota. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; response deadline was July 26, 2023. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program without a binding contract award but signaling intent to formalize procurement through a subsequent RFP. The Minnesota Department of Administration's MMCAP cooperative purchasing alliance posted RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness July 1, 2026. The code's mismatch with actual solicitation scope suggests vendors should monitor issuing-body notices and cooperative vehicle postings directly rather than relying on UNSPSC 51142650 as a reliable search criterion for pharmaceutical procurement opportunities.